The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1321
September 21, 2009
View Complete Issue         Table of Contents 2019 
Artemether-Lumefantrine (Coartem) for Treatment of Malaria
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Artemether-Lumefantrine (Coartem) for Treatment of Malaria
September 21, 2009 (Issue: 1321)
The FDA has approved artemether-lumefantrine (Coartem - Novartis) for oral treatment of uncomplicated Plasmodium falciparum malaria. It is not approved for prophylaxis. Artemether-lumefantrine is the first artemisinin-based drug approved for use in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Artemether-Lumefantrine (Coartem) for Treatment of Malaria
Article code: 1321c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.